CD95 _ FAS
- Known as:
- CD95 _ Fas Cell Surface Death Receptor
- Catalog number:
- GTX75106
- Product Quantity:
- 200 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- CD95 _ FAS
Related genes to: CD95 _ FAS
- Gene:
- FAS NIH gene
- Name:
- Fas cell surface death receptor
- Previous symbol:
- FAS1, APT1, TNFRSF6
- Synonyms:
- CD95, APO-1
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD95 _ FAS
Related articles to: CD95 _ FAS
- The aim of this study was to describe and compare the fatty acid (FA) profiles of hepatic tissue in farmed and wild channel catfish (, Rafinesque, 1818). Thirty-four liver samples were collected from farmed and wild channel catfish. After FA samples were extracted, their fatty acid profiles were obtained by gas chromatography with a flame ionization detector (GC-FID). The analysis revealed that monounsaturated FAs were present at higher concentrations in farmed organisms (161.45 mg/100 g) than in wild organisms (46.87 mg/100 g). While the most abundant FA group in wild organisms was saturated FAs (58.48 mg/100 g), farmed catfish had higher levels (73.22 mg/100 g). The farmed organisms also presented a higher total concentration of FA (296.03 mg/100 g), which is double the mean obtained in wild channel catfish (131.89 mg/100 g). Nonsignificant differences were found in the polyunsaturated, omega-3 and omega-6 quantities, yet a suggestive difference was found for EPA. Our findings suggest that the fatty acid content in the liver is notably different between wild and farm origins. The differences identified in this study were attributed to differential feeding patterns in the analyzed populations of farmed and wild channel catfish. - Source: PubMed
Publication date: 2025/12/20
Esparza-Acebo Leilany MargaritaPerales-Torres Adriana LeticiaDe la Rosa-Reyna Xochitl FabiolaRodríguez-Castillejos Guadalupe ConcepciónEsquivel Aldo VegaMontelongo-Alfaro Isidro OtonielBenavides-González FlavianoParra-Bracamonte Gaspar Manuel - Reducing dietary nutrient density may lower the feed cost but compromise the growth performance in piglets. Given the ability of lysolecithin (LPI) to enhance nutrient utilization, its supplementation may help piglets adapt to a low-nutrient (LN) diet. This study aimed to investigate the effects of dietary LPI supplementation on growth performance, nutrient utilization, metabolism, and muscle development in piglets fed a LN diet. A total of 96 nursery piglets (17.0 ± 0.2 kg in initial body weight [BW] and 50 d of age) were randomly assigned to three groups in a randomized complete block design and received either the normal-nutrient diet (CON), a LN diet, or the LN diet supplemented with 400 mg/kg lysolecithin (LN-LPI) for 28 d. Each dietary treatment included 8 replicates of 4 piglets each. Results showed that the LN-LPI diet improved the average daily gain (ADG; = 0.040) during the first two weeks, feed-to-gain ratio (F:G; = 0.032), and BW ( = 0.065) throughout the experimental period, reaching levels comparable to those of piglets in the CON group. Compared with the LN diet, the growth-promoting effect of LPI may be attributed to its role in increasing the digestibility of ether extract (EE; < 0.001) and gross energy (GE; = 0.022) in diets, as well as increasing the relative weight of psoas major muscles (PMM) and the EE ( = 0.049) and crude protein (CP) content ( = 0.007) in muscle. Accordingly, compared with the LN diet, LPI supplementation decreased the blood urea nitrogen ( = 0.003) and total cholesterol (TC) concentrations ( = 0.017), and increased total superoxide dismutase (T-SOD) levels in plasma ( = 0.005) and liver ( = 0.006), along with the lower malondialdehyde (MDA) levels in blood ( < 0.001) and liver ( = 0.003). In addition, microarray analysis indicated that dietary LPI supplementation promoted expression of lipid synthesis and transport-related genes in the liver (, = 0.040; , = 0.001; and , = 0.025), and amino acid (AA) transport and synthesis-related genes (, = 0.021; , = 0.004), compared with the LN diet in muscle. In conclusion, this study demonstrated that the LN-LPI diet mitigated the compromised growth performance commonly observed under nutrient restriction, potentially mediated by improving nutrient utilization and redox status, and modulating lipid and protein metabolism. - Source: PubMed
Publication date: 2026/06/08
Song HuaqiZhang ZhimingYao RenjieZhou QiangLiu YangJin JinJin JunqiLuo ZhengTang JiayongFeng BinXu ShengyuLin YanHua LunZhuo YongWu DeChe Lianqiang - Enhanced de novo lipogenesis (DNL) is a hallmark of metastatic breast cancer (BC). Environmental exposure to endocrine-disrupting chemicals (EDCs), including bisphenols (such as BPA), is strongly linked to altered lipid metabolism and breast cancer. However, the linkage between EDC-mediated DNL and metastatic transformation in BC remains poorly understood. Here, we demonstrate that long-term exposure to BPA stimulates DNL in both estrogen-sensitive (MCF-7) and triple-negative breast cancer (TNBC) cells (MDA-MB-231) by activating PPARγ/ACC/FAS-driven lipogenic signaling. Moreover, this signalling regulates the migratory and invasive abilities of both BC cell types by inducing epithelial-mesenchymal transition (EMT). Pharmacological inhibition of PPARγ suppressed BPA-induced DNL, vis-à-vis EMT, in both BC cells. Furthermore, BPA-induced GPER1, a membrane-bound estrogen receptor (ER), was found to regulate PPARγ/ACC/FAS-mediated lipogenic signaling, subsequently affecting DNL and EMT in BC cells. Pharmacological inhibition or transient siRNA-mediated knockdown of GPER1 prevented BPA-induced PPARγ/ACC/FAS-driven DNL and EMT in both BC cell lines. Overall, we provide a novel mechanistic link between EDCs and DNL that promotes BC metastasis via GPER1-dependent activation of lipogenic PPARγ/ACC/FAS signaling in both TNBC and ERα-positive BC cells. Hence, GPER1 may act as a signalling hub to mediate EDC-associated DNL-like modifications in BC cells, thereby fueling epithelial-mesenchymal plasticity. - Source: PubMed
Publication date: 2026/08/14
Ansari Mohammad ImranPal AnjaliBano NuzhatKainat Yadav Satya PrakashSharma Pradeep Kumar - The quality of the buried interface between the self-assembled molecules (SAM) and the perovskite layer directly governs the processes of charge carrier transport and non-radiative recombination, which ultimately dictates the efficiency and stability of the inverted perovskite solar cells. However, the simultaneous mitigation of poor SAM layer adhesion and perovskite substrate interface defects remains a significant challenge. Herein, low-cost and readily available 2‑formylbenzenesulfonic acid sodium salt (2‑FAS) is employed as a bifunctional interlayer to molecularly bridge the SAM and perovskite. The benzene ring of 2‑FAS interacts via π-π stacking with the SAM, strengthening adhesion and promoting hole transfer, while its sulfonate group (-SO) coordinates with Pb to regulate crystallization and passivate surface defects. As a result, the 2-FAS-modified devices deliver a champion power conversion efficiency of 26.21%, with a significant fill factor of 86.15%. Furthermore, Na from 2‑FAS occupies A‑site vacancies in the perovskite lattice, which effectively suppresses ion migration and phase transition, thereby enhancing structural integrity. Benefiting from these combined effects, unencapsulated devices retain over 90% of their initial PCE after 4500 h of storage in a nitrogen atmosphere, demonstrating exceptional long-term stability. - Source: PubMed
Publication date: 2026/08/14
Zha LeyingDing WeiluGao YalinWu XiaoSong TingluLi ChanghuaDuan ChenghaoLu XinhuiCai GuilongZhang Suojiang - BackgroundHyaluronic acid (HA) has emerged as a potential biologic adjunct in the management of various foot and ankle pathologies due to its viscoelastic, anti-inflammatory, and chondroprotective properties.MethodsA scoping review of the currently available literature evaluating HA use in foot and ankle pathology was performed, with emphasis on osteoarthritis (OA), osteochondral lesions of the talus (OLTs), and soft tissue disorders.ResultsCurrent evidence suggests that HA injections may provide pain relief and functional improvement across multiple foot and ankle conditions. The most consistent evidence supports potential HA use in soft tissue disorders, including Achilles tendinopathy, plantar fasciitis, and acute lateral ankle injuries. HA may be used as an adjunct in OLT and selected OA applications, although outcomes remain heterogeneous across studies.ConclusionAlthough HA demonstrates a favorable safety profile and potential clinical benefit in selected foot and ankle conditions, currently available evidence remains limited by heterogeneous study designs, inconsistent treatment protocols, and short-term follow-up. Additional high-quality, comparative, and long-term studies are warranted to better define the role of HA in foot and ankle pathology.Level of Evidence:. - Source: PubMed
Publication date: 2026/08/14
Rubin JaredTham AlexanderAllen MichaelButler James JMontgomery Samuel RMercer Nathaniel PLezak Bradley AZaifman JayKennedy John G